News and Events

Paris, France et Camberley, Royaume-Uni – 19 février 2020 – Novacyt (ALTERNEXT : ALNOV ; AIM : NCYT), un spécialiste international du diagnostic clinique, annonce qu’il a émis un total de 6 370 728 nouvelles actions ordinaires de €1/15 chacune dans le capital de la société (“Actions Ordinaires”) suite à l’exercice de bons de souscription

Paris, France and Camberley, UK – 19 February 2020 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that it has issued a total of 6,370,728 new ordinary shares of €1/15 each in the capital of the Company (“Ordinary Shares”) pursuant to the exercise of warrants as detailed below. http://novacyt.com/wp-content/uploads/2020/02/Novacyt-final-Exercise-of-Warrants-and-issue-of-equity-ENGLISH-19.02.2020.pdf

Paris, France et Camberley, Royaume-Uni – 19 février 2020 – Novacyt (ALTERNEXT : ALNOV ; AIM : NCYT), spécialiste international du diagnostic clinique, annonce qu’elle a reçu de YA II CD, Ltd un avis d’exercice de bons de souscription de 300 000 de nouvelles actions ordinaires de 1€/15 chacune dans le capital de la société

Paris, France and Camberley, UK – 19 February 2020 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that it has received notice from YA II CD, Ltd of an exercise of warrants to subscribe for 300,000 new ordinary shares of €1/15 each in the capital of the Company (“Ordinary

Paris, France and Camberley, UK – 18 February 2020 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that it has received notice from YA II CD, Ltd of an exercise of warrants to subscribe for 228,541 new ordinary shares of €1/15 each in the capital of the Company (“Ordinary

Paris, France et Camberley, Royaume-Uni – 18 février 2020 – Novacyt (ALTERNEXT : ALNOV ; AIM : NCYT), spécialiste international du diagnostic clinique, annonce qu’elle a reçu de YA II CD, Ltd un avis d’exercice de bons de souscription de 228 541 nouvelles actions ordinaires de 1€/15 chacune dans le capital de la société (“Actions

Paris, France et Camberley, Royaume-Uni – 17 février 2020 – Novacyt (ALTERNEXT : ALNOV ; AIM : NCYT), spécialiste mondial du diagnostic clinique, a le plaisir d’annoncer que sa division de diagnostic moléculaire, Primerdesign, a lancé son test moléculaire CE-Mark pour la détection clinique du nouveau coronavirus (COVID-19). http://novacyt.com/wp-content/uploads/2020/02/Novacyt-CE-mark-approval-coronavirus-test-FR.pdf

Paris, France and Camberley, UK – 17 February 2020 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, is pleased to announce that its molecular diagnostics division, Primerdesign, has launched its CE-Mark molecular test for the clinical detection of the novel coronavirus (COVID-19). http://novacyt.com/wp-content/uploads/2020/02/Novacyt-CE-mark-approval-coronavirus-test-ENG.pdf

Paris, France et Camberley, Royaume-Uni – 14 février 2020 – Novacyt (ALTERNEXT : ALNOV ; AIM : NCYT), spécialiste mondial du diagnostic clinique, a le plaisir d’annoncer que, suite à son annonce du 7 février 2020, sa filiale, Primerdesign Limited, est en mesure de lancer un test du nCoV approuvé par le marquage CE dans

Paris, France and Camberley, UK – 14 February 2020 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, is pleased to announce that, further to its announcement on 7 February 2020, its subsidiary, Primerdesign Limited, is on schedule to launch a CE-Mark approved nCoV test in the week commencing 17 February